Clinical Trial Update: The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating everolimus-based immunosuppression in the progression of hepatitis C–related fibrosis after liver transplantation has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis Recurrence After Liver Transplantation

Drugs mentioned

• Everolimus (everolimus)

Snippet

Sponsor: Hospital Vall d'Hebron | Conditions: Hepatitis C Recurrence After Liver Transplant | Phase 3 | Status: COMPLETED